Spotlight Center on HIV Prevention Today

Medical News

Antiretroviral Drug Researchers, AIDS Advocates Fail to Reach Consensus Over Viread Trials in Developing Countries

May 24, 2005

This article is part of The Body PRO's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.

Antiretroviral drug researchers, study sponsors and AIDS advocates in a meeting that began last week in Seattle reached some agreement but failed to resolve completely conflicts over the conduct of clinical trials testing whether the antiretroviral drug Viread, which is made by the pharmaceutical company Gilead, can prevent HIV infection among people in developing countries, the Wall Street Journal reports (Chase, Wall Street Journal, 5/24). At issue is whether researchers should provide lifelong antiretroviral treatment -- not just a referral for care -- to people who become HIV-positive while participating in the trials. Protests organized by ACT UP/Paris and other European AIDS organizations demanding such care have led to the cancellation of Viread studies in Cambodia and the suspension of trials in Cameroon. However, researchers say that offering lifelong treatment to volunteers might violate a prohibition on undue inducement to participate in clinical trials. In addition, some AIDS advocates want injection drug users participating in a Viread trial in Thailand to be provided with clean needles. However, the trials are using U.S. funding, and providing clean needles would breach a congressional ban on the practice (Kaiser Daily HIV/AIDS Report, 5/18).

Meeting Outcome
At the meeting -- which was sponsored by the International AIDS Society -- patient advocates met with representatives of the Bill & Melinda Gates Foundation, NIH and CDC. Conferees agreed that trial volunteers should receive more HIV prevention counseling and barrier contraceptives, including female condoms. A report resulting from the meeting said efforts to counsel volunteers were sometimes "ill-informed and inconsistent," according to the Journal. However, the meeting did not resolve the dispute over the provision of lifelong antiretroviral treatment for people who become HIV-positive while participating in the studies. The conferees agreed that "mechanisms" to ensure treatment needed to be established, but they did not agree on the important question of who would pay for treatment, according to the Journal (Wall Street Journal, 5/24).

Back to other news for May 24, 2005


Reprinted with permission from You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at The Kaiser Daily HIV/AIDS Report is published for, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.